The expected outcome of a CLIN2 award is completion of a single interventional clinical trial. CIRM anticipates funding between 9-16 CLIN2 awards in fiscal year 2025-2026, contingent on the number of ...

Objetivo de la investigación Esta propuesta esclarecerá los mecanismos que identifican una población de células madre/progenitoras en la placenta humana. Impacto Esta propuesta aborda nuestra brecha ...

South San Francisco, CA, April 24, 2025 — The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has approved awarding ...

Diabetes exacts a tremendous toll on patients, their families, and society in general. Autoimmune Type 1 diabetes, often called juvenile-onset diabetes, is caused by a person’s own immune system ...

Current treatment options for dry mouth/xerostomia, such as oral pills and rinses, merely alleviate symptoms but fail to address the underlying cause of dry mouth. With no regenerative treatments ...

The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse ...

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients. CIRM funds clinical trials across a broad ...

Welcome to the frequently asked questions (FAQs) page of the California Institute for Regenerative Medicine (CIRM). Here, you’ll find answers to the most common questions you may have on CIRM. CIRM, ...

CIRM funds stem cell research to institutions throughout California. On the map below, click on any marker to learn more about our funding to that institution. You can explore the awards they’ve ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

Foundation – Discovery Stage Research Projects Qiong Annabel Wang Utilizing Age-Specific Adipocyte Progenitor Cells for Cell Therapy in Older Patients $1,508,997 Clinical Trial Stage Projects Prof.